دورية أكاديمية
Tat-dependent conditionally replicating adenoviruses expressing diphtheria toxin A for specifically killing HIV-1-infected cells.
| العنوان: | Tat-dependent conditionally replicating adenoviruses expressing diphtheria toxin A for specifically killing HIV-1-infected cells. |
|---|---|
| المؤلفون: | Ni F; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P.R. China., Hu K; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China., Li M; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P.R. China., Yang M; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China., Xiao Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China., Fu M; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China., Zhu Z; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P.R. China., Liu Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Hubei Jiangxia Laboratory, Wuhan 430200, P.R. China. Electronic address: liuyl@wh.iov.cn., Hu Q; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, P.R. China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P.R. China. Electronic address: qhu@wh.iov.cn. |
| المصدر: | Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Jul 03; Vol. 32 (7), pp. 2316-2327. Date of Electronic Publication: 2024 May 11. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Cambridge, MA : Cell Press Original Publication: San Diego, CA : Academic Press, 2000- |
| مواضيع طبية MeSH: | HIV-1*/genetics , Diphtheria Toxin*/genetics , Virus Replication* , Adenoviridae*/genetics , HIV Infections*/therapy , tat Gene Products, Human Immunodeficiency Virus*/genetics , tat Gene Products, Human Immunodeficiency Virus*/metabolism , Genetic Therapy*/methods , Genetic Vectors*/genetics, Humans ; Animals ; Mice ; Disease Models, Animal ; Cell Line ; HEK293 Cells ; Gene Expression ; Peptide Fragments |
| مستخلص: | HIV-1 infection remains a public health problem with no cure. Although antiretroviral therapy (ART) is effective for suppressing HIV-1 replication, it requires lifelong drug administration due to a stable reservoir of latent proviruses and may cause serious side effects and drive the emergence of drug-resistant HIV-1 variants. Gene therapy represents an alternative approach to overcome the limitations of conventional treatments against HIV-1 infection. In this study, we constructed and investigated the antiviral effects of an HIV-1 Tat-dependent conditionally replicating adenovirus, which selectively replicates and expresses the diphtheria toxin A chain (Tat-CRAds-DTA) in HIV-1-infected cells both in vitro and in vivo. We found that Tat-CRAds-DTA could specifically induce cell death and inhibit virus replication in HIV-1-infected cells mediated by adenovirus proliferation and DTA expression. A low titer of progeny Tat-CRAds-DTA was also detected in HIV-1-infected cells. In addition, Tat-CRAds-DTA showed no apparent cytotoxicity to HIV-1-negative cells and demonstrated significant therapeutic efficacy against HIV-1 infection in a humanized mouse model. The findings in this study highlight the potential of Tat-CRAds-DTA as a new gene therapy for the treatment of HIV-1 infection. Competing Interests: Declaration of interests Q.H., F.N., K.H., and Y.L. are listed as inventors on a pending patent (CN 202310933875.6) related to the construction and application of the recombinant viral vector. (Copyright © 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.) |
| References: | N Engl J Med. 2014 Mar 6;370(10):901-10. (PMID: 24597865) Hum Gene Ther. 1991 Spring;2(1):53-60. (PMID: 1863640) Front Cell Infect Microbiol. 2022 Jul 28;12:945956. (PMID: 35967854) Nat Med. 2023 Mar;29(3):583-587. (PMID: 36807684) Lancet HIV. 2020 May;7(5):e340-e347. (PMID: 32169158) J Virol. 2022 Apr 27;96(8):e0003422. (PMID: 35384694) J Clin Invest. 2018 Jun 1;128(6):2239-2251. (PMID: 29461979) J Virol. 2023 Oct 31;97(10):e0101423. (PMID: 37712705) Rev Cardiovasc Med. 2014;15 Suppl 1:S21-9. (PMID: 24987860) Hum Gene Ther. 2015 Oct;26(10):680-7. (PMID: 26077977) Virol J. 2021 Jan 30;18(1):31. (PMID: 33516234) N Engl J Med. 2024 Feb 15;390(7):669-671. (PMID: 38354149) Mol Vis. 2008;14:2535-46. (PMID: 19122827) Protein Sci. 1994 Sep;3(9):1464-75. (PMID: 7833808) N Engl J Med. 2009 Feb 12;360(7):692-8. (PMID: 19213682) Mol Ther. 2022 Dec 7;30(12):3639-3657. (PMID: 35949171) Cancer Biol Ther. 2016 Jun 2;17(6):664-73. (PMID: 27195521) Pharmaceutics. 2019 Jun 01;11(6):. (PMID: 31159417) Lancet Infect Dis. 2013 Jul;13(7):614-21. (PMID: 23481675) Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16538-43. (PMID: 24043801) Cell. 2023 Mar 16;186(6):1115-1126.e8. (PMID: 36931242) J Control Release. 2023 Mar;355:538-551. (PMID: 36063962) Cancer Gene Ther. 2006 Sep;13(9):845-55. (PMID: 16710344) Cancer Res. 2003 Jun 15;63(12):3181-8. (PMID: 12810646) BMC Cancer. 2019 May 29;19(1):516. (PMID: 31142289) N Engl J Med. 2014 Aug 28;371(9):880-2. (PMID: 25162903) N Engl J Med. 1997 Sep 11;337(11):734-9. (PMID: 9287228) Virus Res. 2011 Jan;155(1):48-54. (PMID: 20801174) J Gen Virol. 2015 Aug;96(8):2381-2393. (PMID: 25854553) Nat Protoc. 2007;2(5):1236-47. (PMID: 17546019) J Infect Dis. 2000 Feb;181 Suppl 1:S156-67. (PMID: 10657208) Biochem Pharmacol. 2022 Mar;197:114893. (PMID: 34968484) Vaccine. 2018 Jul 5;36(29):4287-4297. (PMID: 29885770) Hum Gene Ther. 1995 Nov;6(11):1437-45. (PMID: 8573616) Cells. 2023 Dec 28;13(1):. (PMID: 38201268) AIDS Rev. 2015 Jan-Mar;17(1):65. (PMID: 25608470) Appl Microbiol Biotechnol. 2024 Jan 27;108(1):179. (PMID: 38280035) Expert Rev Anti Infect Ther. 2016;14(1):29-40. (PMID: 26513236) PLoS One. 2023 Dec 1;18(12):e0293046. (PMID: 38039314) J Virol. 2000 Mar;74(6):2567-83. (PMID: 10684271) Biochimie. 2021 Nov;190:24-35. (PMID: 34242726) Drug Deliv Transl Res. 2022 Oct;12(10):2561-2568. (PMID: 35098492) Mol Ther. 2021 Feb 3;29(2):626-635. (PMID: 33186691) J Infect Dis. 2008 Mar 1;197(5):714-20. (PMID: 18260759) Blood. 2011 May 26;117(21):5582-90. (PMID: 21403129) Cancer Biol Ther. 2017 Nov 2;18(11):833-840. (PMID: 29144842) Cancer Gene Ther. 1999 Mar-Apr;6(2):113-38. (PMID: 10195879) |
| فهرسة مساهمة: | Keywords: conditionally replicating adenoviruses; diphtheria toxin A chain; gene therapy; human immunodeficiency virus type 1; long terminal repeat |
| المشرفين على المادة: | 0 (Diphtheria Toxin) 0 (tat Gene Products, Human Immunodeficiency Virus) 0 (diphtheria toxin fragment A) 0 (Peptide Fragments) |
| تواريخ الأحداث: | Date Created: 20240512 Date Completed: 20240704 Latest Revision: 20240801 |
| رمز التحديث: | 20240801 |
| مُعرف محوري في PubMed: | PMC11286811 |
| DOI: | 10.1016/j.ymthe.2024.05.015 |
| PMID: | 38734901 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1525-0024 |
|---|---|
| DOI: | 10.1016/j.ymthe.2024.05.015 |